Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...

Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

Rhythm Pharmaceuticals, Inc. (RYTM) shares soared 5.5% in the last trading session to close at $57.52. The move was backed by solid volume with far more shares changing hands than in a normal session.

Rhythm Pharmaceuticals has a 52 week low of $35.17 and a 52 week high of $68.58. Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last released its earnings results on Wednesday, February ...

Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million during the quarter, compared to analyst estimates ...

Given this risk, we thought we'd take a look at whether Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual ...

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.70 per share a year ago.